Searchable abstracts of presentations at key conferences in endocrinology

ea0025p307 | Steroids | SFEBES2011

Epidemiology of Addison's disease in the area of banbury, oxfordshire

Komninos John , Kohler Sybil , Karavitaki Niki , Wass John

Introduction: Addison’s disease (AD) is a rare condition (reported prevalence of 40–110 per million) that requires prompt recognition and optimal management to prevent the risks associated with cortisol deficiency.Aim: To assess the prevalence, presentation and clinical course of patients diagnosed with AD in the geographical area of Banbury in Oxfordshire.Patients and methods: Notes of subjects with AD currently register...

ea0022p571 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Long-term morbidities in patients with Cushing's disease

Ntali Georgia , Siamatras Thomas , Komninos John , Karavitaki Niki , Wass John

Introduction: Cushing’s disease (CD) is a rare condition, associated with significant morbidities and potentially fatal, if untreated.Objective: To assess the long-term morbidities in a large series of patients with CD during a prolonged follow-up period.Patients and methods: All subjects with CD who presented/followed-up in our Department between 01/1967 and 06/2009 were studied. All information was collected as documented in...

ea0021p262 | Pituitary | SFEBES2009

Prolonged remission of acromegaly after cessation of somatostatin analogue treatment

Thornton-Jones Vivien , Karavitaki Niki , Wass John A H

Introduction: The concept of life-long medical therapy for acromegaly has recently been challenged. Hormonal remission for up to 48 months after stopping somatostatin analogues in acromegalic patients has recently been reported. Herein, we present a further case showing the longest remission yet in growth hormone levels after somatostatin analogue treatment.Case: In 1987, a 43 year old man was diagnosed with acromegaly [nadir GH on oral glucose tolerance...

ea0021p312 | Reproduction | SFEBES2009

Clinical experience of Nebido: monitoring the efficacy and safety of testosterone undecanoate in men over 60 years of age

Mantripp Diana , Smith Rachel , Karavitaki Niki , Wass John

Aim: In normal men testosterone levels fall with age. We wished to assess the efficacy and safety of Nebido in men over the age of 60 years in order to assess dose frequency and other potential complications.Subjects and methods: Ten men over 60 years of age (range 60–77 median 64) with primary or secondary hypogonadism were treated with Nebido 1000 mg i.m. Each was given a loading dose of two injections 6 weeks apart (our normal protocol for all pa...

ea0021p406 | Thyroid | SFEBES2009

Diagnostic and financial benefits of checking TSH receptor antibodies in patients with thyrotoxicosis

Fazal-Sanderson Violet , Aung Theingi , Wass John A H , Karavitaki Niki

Background: TSH-receptor stimulating antibodies are implicated in the pathophysiology of Graves’ disease (GD). The detection of TSH-receptor antibodies (TSHR-Abs) is routinely performed by assays measuring thyrotropin-binding inhibitor immunoglobulin and new generation assays are reported to have high sensitivity and specificity in GD. The differentiation of hyperthyroidism (GD or toxic multinodular goiter (TMG) or toxic adenoma (TA)) is important for planning the therapy...

ea0019p58 | Clinical practice/governance and case reports | SFEBES2009

An interesting case of Turner syndrome with spontaneous pregnancies

Aung Theingi , Meston Niki , Shears Debbie , Karavitaki Niki , Wass JAH

Turner syndrome results from the complete or partial lack of one X chromosome and occurs in approximately 1:2500 female live births. The incidence of spontaneous puberty in the 45, X karyotype is about 9%. Spontaneous pregnancy has been reported in less than 5% of the cases, the majority of which have been described in subjects with mosaicism; these are often associated with high rates of miscarriage and stillbirth.A 51-year-old check-out supervisor was ...

ea0019p242 | Pituitary | SFEBES2009

An analysis of the dose of levothyroxine in patients with central hypothyroidism

Diacono Fabrizio , Bilbao Ismene , Karavitaki Niki , Wass John AH

Background: Levothyroxine is the standard treatment for central hypothyroidism (CH). Studies assessing the optimal dose are limited and include subjects with other untreated pituitary hormone deficits, affecting the interpretation of results. A reliable comparison with the dose used in primary hypothyroidism (PH) has not been reported.Aims: To evaluate daily and body-weight-adapted levothyroxine dose (BWA-dose) in a cohort of patients with CH on appropri...

ea0019p289 | Reproduction | SFEBES2009

The importance of a specialized adult Turner Syndrome clinic

Aung Theingi , Meston Niki , Bilbao Ismene , Karavitaki Niki , Wass JAH

Background: Turner syndrome (TS) affects 1:2500 live births. Mean age of death is reported 27.9±25.5 years due to cardiovascular complications. Expert care is required for better outcome.Aim: To review data on presentation and follow-up of a large series of patients with TS attending our Adult TS clinic.Patients and methods: The records of 64 out of 72 patients were available for review.Results: About 56...

ea0019p391 | Thyroid | SFEBES2009

Thyroid nurse-led clinic service: a positive healthcare initiative

Fazal-Sanderson Violet , Wass John AH , Karavitaki Niki

Background: Patients with uncomplicated hyperthyroidism referred by their GP to our Department had a waiting time of 3–4 months before been seen by a Consultant. As a result of this, funding was provided for setting-up a Thyroid Nurse-Led Clinic (TNLC) aiming to resolve the problem. The clinic started running in May 2005.Aim: To assess the benefits of the TNLC for the NHS.Patients and methods: The data of visits of patients se...

ea0019p392 | Thyroid | SFEBES2009

A thyroid nurse-led service: patients’ perspective: an audit

Fazal-Sanderson Violet , Wass John AH , Karavitaki Niki

Background: A Thyroid Nurse-Led Clinic (TNLC) was set up within the Department of Endocrinology in Oxford aiming primarily to reduce waiting times of patients with uncomplicated thyrotoxicosis from 3 to 4 months to 2 to 4 weeks. It proved to be a cost effective measure.Aims: To explore the patients’ perspective on the provision of care and on the service delivery of the TNLC.Patients and methods: A structured questionnaire wit...